Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $127.95 in the last session, down -0.02% from day before closing price of $127.97. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 3.83 million shares were traded.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 2.08 whereas as Long-Term Debt/Eq ratio is at 1.72.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 03 ’25 when Carter Percy H. sold 2,659 shares for $127.88 per share. The transaction valued at 340,033 led to the insider holds 54,206 shares of the business.
Albers Jeffrey W. sold 5,000 shares of BPMC for $505,692 on May 27 ’25. The Director now owns 146,630 shares after completing the transaction at $101.14 per share. On May 27 ’25, another insider, Albers Jeffrey W., who serves as the Director of the company, bought 5,000 shares for $101.14 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 14.72 while its Price-to-Book (P/B) ratio in mrq is 24.15.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $128.24, while it has fallen to a 52-week low of $73.04. The 50-Day Moving Average of the stock is 30.53%, while the 200-Day Moving Average is calculated to be 34.95%.
Shares Statistics:
A total of 64.56M shares are outstanding, with a floating share count of 62.30M. Insiders hold about 3.67% of the company’s shares, while institutions hold 106.82% stake in the company.
